Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 108 results for melanoma

  1. Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)

    Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

    Technology appraisal guidance
    Published
    26 October 2016
    View recommendations

    Sections for TA414

  2. Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA684)

    Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease in adults.

    Technology appraisal guidance
    Published
    17 March 2021
    View recommendations

    Sections for TA684

  3. Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)

    Evidence-based recommendations on nivolumab–relatlimab (Opdualag) for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over.

    Technology appraisal guidance
    Published
    7 February 2024
    View recommendations

    Sections for TA950

  4. Skin cancer (QS130)

    This quality standard covers preventing, assessing, diagnosing and managing skin cancer (melanoma and non-melanoma skin cancer). It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    24 January 2024
    View quality statements

    Sections for QS130

  5. Lifileucel for previously treated unresectable or metastatic melanoma ID3863

    In development Reference number: GID-TA10752 Expected publication date:  10 July 2026

    Technology appraisal guidance
    In development

  6. Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)

    Evidence-based recommendations on vemurafenib (Zelboraf) for treating advanced BRAF V600-positive malignant melanoma in adults.

    Technology appraisal guidance
    Last updated
    1 January 2015
    View recommendations

    Sections for TA269

  7. Skin cancer prevention (PH32)

    This guideline covers new buildings and communal outdoor areas. The aim is to ensure there are enough shady areas to protect people from overexposure to the sun.

    Public health guideline
    Last updated
    9 February 2016
    View recommendations

    Sections for PH32

  8. Ambulight PDT for the treatment of non-melanoma skin cancer (HTG268)

    Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.

    HealthTech guidance
    Published
    25 July 2011
    View recommendations

    Sections for HTG268

  9. Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal) (TA980)

    NICE is unable to make a recommendation on nivolumab (Opdivo) for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over. This is because Bristol-Myers Squibb did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    5 June 2024

    Sections for TA980

  10. Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]

    Awaiting development Reference number: GID-TA11458 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Digital technologies for the detection of melanoma (MIB311)

    NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .

    Medtech innovation briefing
    Published
    1 November 2022

  12. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

    In development Reference number: GID-IPG10448 Expected publication date: TBC

    Interventional procedures guidance
    In development

  13. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver: draft scope consultation

    We are listening to your views on this Interventional procedures guidance. Comments close 19 December 2025.

    Interventional procedures guidance
    In consultation

  14. Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (IPG446)

    Evidence-based recommendations on electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma. This involves applying short, powerful pulses of electricity to the tumour, allowing an anticancer drug to pass through into the cells.

    Interventional procedures guidance
    Published
    27 March 2013
    View recommendations

    Sections for IPG446

  15. Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (IPG784)

    Evidence-based recommendations on epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer. This involves radioactive paste being spread on foil over the top of the cancer, to destroy the cancer cells.

    Interventional procedures guidance
    Published
    2 April 2024
    View recommendations

    Sections for IPG784